AprilBio Co.,Ltd. (KOSDAQ:397030)
South Korea · Delayed Price · Currency is KRW 51,800
+300 (0.58%)
At close: May 21, 2026
AprilBio Revenue
In the year 2025, AprilBio had annual revenue of 2.17B KRW, down -92.11%.
Revenue
2.17B
Revenue Growth
-92.11%
P/S Ratio
556.70
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.21T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.17B | -25.34B | -92.11% |
| Dec 31, 2024 | 27.51B | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 200.00M | -23.20B | -99.15% |
| Dec 31, 2021 | 23.40B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CORESTEMCHEMON | 20.16B |
| JS Link | 19.32B |
| TiumBio | 12.29B |
| Qurient | 6.98B |
| Kangstem Biotech | 3.57B |
| Inventage Lab | 2.94B |
| Ensol Biosciences | 537.46M |
| ViGenCell | 278.95M |